• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHAO Hua,GUO Shenglan,HUANG Nuanchao,GONG Zhanchao,CHEN Bo,CHEN Junhu,LUO Chongbin.Analysis of multi-drug resistant infection in neonatology of a hospital from 2016 to 2018[J].Journal Of Pharmaceutical Research,2020,39(5):299-303[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3161times   Download 2993次 QR Code for this article
Scan with your phone!
某医院新生儿科2016—2018年351株多重耐药菌感染与用药分析
赵华1,郭胜蓝1,黄暖潮2,龚湛潮2,陈波3,陈俊虎4,罗崇彬1
Font:Larger+|Default|Smaller-
(1.广州市花都区人民医院药学部,广东 广州 510800;2.广州市花都区人民医院新生儿科,广东 广州 510800;3.广州市花都区人民医院医院感染管理科,广东 广州 510800;4.广东省生物制品与药物研究所,广东 广州 510440)
摘要:
目的 了解某院新生儿科多重耐药菌的菌种和耐药情况,指导新生儿科临床合理应用抗菌药物。方法 对某院新生儿科2016~2018年发生的315例新生儿多重耐药菌感染的细菌监测结果进行分析。结果 共检出多重耐药菌株351株,对3~10类抗菌药物耐药。革兰阴性菌273株,占77.8%,其中肺炎克雷伯菌179株排名第一,而产超广谱β内酰胺酶(ESBL)菌株为97株,占27.6%;肺炎克雷伯菌对头孢唑林、头孢呋辛、头孢曲松、头孢他啶耐药率较高,且呈逐年增加的趋势,对头孢噻肟、头孢吡肟的耐药率呈逐年下降趋势;大肠埃希菌对头孢唑林、头孢呋辛、头孢曲松、头孢噻肟、头孢吡肟的耐药率有所下降,但整体耐药率仍达50%以上。革兰阳性菌78株,占22.2%,其中以表皮葡萄球菌、溶血性葡萄球菌、金黄色葡萄球位列前三。革兰阳性菌对氨苄西林/舒巴坦、阿莫西林/克拉维酸、青霉素、氨苄青霉素、苯唑西林、头孢曲松耐药均达100%,对万古霉素、利耐唑胺、莫西沙星、奎奴普丁/达福普丁、达托霉素均高度敏感。结论 该院新生儿科多重耐药菌感染的病原菌主要以革兰阴性杆菌为主,且对大部分抗菌药物产生了耐药。
关键词:  新生儿  多重耐药菌  感染  抗菌药物
DOI:10.13506/j.cnki.jpr.2020.05.012
基金项目:
Analysis of multi-drug resistant infection in neonatology of a hospital from 2016 to 2018
ZHAO Hua1,GUO Shenglan1,HUANG Nuanchao2,GONG Zhanchao2,CHEN Bo3,CHEN Junhu4,LUO Chongbin1
(1.Department of Pharmacy, Huadu District People's Hospital, Guangzhou 510800,China;2.Department of Neonatology, Huadu District People's Hospital, Guangzhou 510800,China;3.Department of Infectious Diseases, Huadu District People's Hospital, Guangzhou 510800,China;4.Guangdong Institute of Biological Products and Medicine,Guangzhou 510440,China)
Abstract:
Objective To understand the strains and drug resistance of multi-drug resistant strains in neonatology in our hospital, and to guide the rational application of antibiotics in neonatology.Methods A total of 315 neonatal bacterial surveillance results of multi-drug resistant infections from 2016 to 2018 in the neonatology department of our hospital were analyzed.Results A total of 351 multi-drug resistant strains and 273 Gram-negative bacteria were detected, accounting for 77.8%. Among them, 179 strains of Klebsiella pneumoniae ranked first, while strains producing extended-spectrum β-lactamase (ESBL) strain were 97 strains, accounting for 27.6%; Klebsiella pneumoniae resistance to cefazolin, cefuroxime, ceftriaxone, ceftazidime is higher, and is increasing year by year, the resistance rate to cefotaxime, cefepime. The trend of declining year by year; the resistance rate of Escherichia coli to cefazolin, cefuroxime, ceftriaxone, cefotaxime, cefepime decreased, but the overall resistance rate still reached more than 50%. There were 78 Gram-positive bacteria, accounting for 22.2%. The top three were Staphylococcus epidermidis, Staphylococcus aureus and Staphylococcus aureus.Gram-positive bacteria resistant to ampicillin/sulbactam, amoxicillin/clavulanic acid, penicillin, ampicillin, oxacillin, ceftriaxone 100%, to vancomycin, linezolid lizolamide, mo Xishaxing, quinupristin/dalofopidine, and daptomycin are highly sensitive. 351 multi-drug resistant strains were resistant to 3-10 antibiotics.Conclusion The pathogens of multidrug-resistant bacteria in the neonatology department of our hospital are mainly Gram-negative bacteria, which are resistant to most antibiotics.
Key words:  Newborns  Multi-drug resistant bacteria  Infections  Antibiotics
Today's Visits:483    Total Visits:2383194
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.